Role of statins in acute coronary syndromes

References

• Scandinavian Simvastatin Survival Study Group. Ran-domised trial of cholesterol lowering in /111114 patients with coronary heart disease: the Scandinavian Simvastatin Sur-vival Study (4S). Lancet 1994; 344: 1383–9.
   Google Scholar
• Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Ruther-ford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001–9.
   Google Scholar
• Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hyper-cholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301–7.
   Google Scholar
• Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coro-nary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615–22.
   Google Scholar
• Long-Term Intervention with Pravastatin in Ischaemic Dis-ease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349–57.
   Google Scholar
• Pitt B, Mancini GB, Ellis SG, Rosman HS, Park JS, McGovern ME. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation. J Am Coll Cardiol 1995; 26: 1133–9.
   Google Scholar
• Brown BG, Zhao XQ, Sacco DE, Albers JJ. Lipid lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993; 87: 1781–91.
   Google Scholar
• Vaughan CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet 1996; 348: 1079–82.
   Google Scholar
• Mintz GS, Painter JA, Pichard AD, Kent KU, Satler LF, Popma JJ, Chuang YC, Bucher TA, Sokolowicz LE, Leon MB. Atherosclerosis in angiographically “normal” coronary artery reference segments: an intravascular ultra-sound study with clinical correlations. J Am Coll Cardiol 1995; 25: 1479–85.
   Google Scholar
• Mintz GS, Popma JJ, Pichard AD, Kent KM, Satler LF, Wong C, Hong MK, Kovach JA, Leon MB. Arterial remod-eling after coronary angioplasty: a serial intravascular ultra-sound study. Circulation 1996; 94: 35–43.
   Google Scholar
• Little WC. Angiographic assessment of the culprit coronary artery lesion before acute myocardial infarction. Am J Cardiol 1990; 66(suppl): 44G–47G.
   Google Scholar
• Little WC, Downes TR, Applegate RJ. The underlying coronary lesion in myocardial infarction: implications for coronary angiography. Clin Cardiol 1991; 14: 868–74.
   Google Scholar
• Ogawa H, Kawana M, Tamura K, Kimata S, Hosoda S. Long-term prognosis of medically treated patients with acute myocardial infarction and one-vessel coronary artery dis-ease. Am J Cardiol 1994; 73: 158–63.
   Google Scholar
• Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001; 285: 1711–8.
   Google Scholar
• Davies M. Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995. Circulation 1996; 94: 2013–20.
   Google Scholar
• Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000; 101: 207–13.
   Google Scholar
• Forrester JS, Shah PK. Lipid lowering versus revascularisa-tion: an idea whose time (for testing) has come. Circulation 1997; 96: 1360–2.
   Google Scholar
• Fuster V, Lewis A. Conner Memorial Lecture. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation 1994; 90: 2126–46.
   Google Scholar
• Walter DH, Fichtlscherer S, Britten MB, Auch-Schwelk W, Schachinger V, Zeiher AM. Benefits of immediate initiation of statin therapy following successful coronary stent implan-tation in patients with stable and unstable angina pectoris and Q-wave acute myocardial infarction. Am J Cardiol 2002; 89: 1–6.
   Google Scholar
• Wayman NS, Ellis BL, Thiemermann C. Simvastatin reduces infarct size in a model of acute myocardial ischemia and reperfusion in the rat. Med Sci Monit 2003; 9: BR155–9.
   Google Scholar
• Stefanadis C, Toutouzas K, Vavuranakis M, Tsiamis E, Tousoulis D, Panagiotakos DB, Vaina S, Pitsavos C, Toutouzas P. Statin treatment is associated with reduced thermal heterogeneity in human atherosclerotic plaques. Eur Heart J 2002; 23: 1664–9.
   Google Scholar
• Egashira K, Hirooka Y, Kai H, Sugimachi M, Suzuki S, Inou T, Takeshita A. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vaso-motion in patients with hypercholesterolemia. Circulation 1994; 89: 2519–24.
   Google Scholar
• Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS, Zhang J, Boccuzzi SJ, Cedarholm JC, Alexander RW. Beneficial effects of choles-terol lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995; 332: 481–7.
   Google Scholar
• Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998; 97: 1129–35.
   Google Scholar
• Dupuis J, Tardif JC, Cemaceck P, Theroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (Reduction of Choles-terol in Ischemia and Function of the Endothelium) Trial. Circulation 1999; 99: 3227–33.
   Google Scholar
• Delanty N, Vaughan CJ. Vascular effects of statins in stroke. Stroke 1997; 28: 2315–20.
   Google Scholar
• Blauw GJ, Lagaay AM, Smelt AHM, Westendorp RGJ. Stroke, statins, and cholesterol: a meta-analysis of random-ized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. Stroke 1997; 28: 946–50.
   Google Scholar
• Furberg CD, Adams HP Jr, Applegate WB, Byington RP, Espeland MA, Hartwell T, Hunninghake DB, Lefkowitz DS, Probstfield J, Riley WA, Young B. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation 1994; 90: 1679–87.
   Google Scholar
• Crouse JR 3rd, Byington RP, Bond MG, Espeland MA, Craven TE, Sprinkle JW, McGovern ME, Furberg CD. Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II). Am J Cardiol 1995; 75: 455–9.
   Google Scholar
• MacMahon S, Sharpe N, Gamble G, Hart H, Scott J, Simes J, White H. Effects of lowering average of below-aver-age cholesterol levels on the progression of carotid athero-sclerosis: results of the LIPID Atherosclerosis Substudy. LIPID Trial Research Group. Circulation 1998; 97: 1784–90.
   Google Scholar
• Crouse JR III, Byington RP, Hoen HM, Furberg CD. Reductase inhibitor monotherapy and stroke prevention. Arch Intern Med 1997; 157: 1305–10.
   Google Scholar
• Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with hypercholesterolemia. Circulation 2001; 102: 1191–3.
   Google Scholar
• Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LM, Goldman S, Raker GC, Braunwald E, for the Cholesterol and Recurrent Events (CARE) Investigators. Inflammation, pravastatin and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circu-lation 1998; 98: 839–44.
   Google Scholar
• Plenge JK, Hernandez TL, Weil KM, Poirier P, Grun-wald GK Marcovina SM, Eckel RH. Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation 2002; 106: 1447–52.
   Google Scholar
• Notarbartolo A, Davi G, Avema M, Barbagallo CM, Ganci A, Giammarresi C, La Placa FP, Patrono C. Inhibition of thromboxane biosynthesis and platelet function by simvas-tatin in type IIa hypercholesterolemia. Arterioscler Thromb Vasc Biol 1995; 15: 247–51.
   Google Scholar
• Mayer J, Eller T, Brauer P, Solleder EM, Schafer RM, Keller F, Kochsiek K. Effects of long-term treatment with lovastatin on the clotting system and blood platelets. Ann Hematol 1992; 64: 196–201.
   Google Scholar
• Lacoste L, Lam JYT, Hung J, Letchacovski G, Solymoss CB, Waters D. Hyperlipidaemia and coronary disease: correc-tion of the increased thrombogenic potential with choles-terol reduction. Circulation 1995; 92: 3172–7.
   Google Scholar
• Armstrong VW, Cremer P, Eberle E, Manke A, Schulze F, Wieland H, Kreuzer H, Seidel D. The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Dependence on serum LDL levels. Atherosclerosis 1986; 62: 249–57.
   Google Scholar
• Lundstam U, Hurt-Camejo E, Olsson G, Sartipy P, Camejo G, Wiklund 0. Proteoglycans contribution to asso-ciation of Lp(a) and LDL with smooth muscle cell extra-cellular matrix. Arterioscler Thromb Vasc Biol 1999; 19: 1162–7.
   Google Scholar
• Maher VM, Brown BG, Marcovina SM, Hillger LA, Zhao XQ, Albers JJ. Effects of lowering elevated LDL cho-lesterol on the cardiovascular risk of lipoprotein(a). JAMA 1995; 274: 1771–4.
   Google Scholar
• DiGarbo V, Bono M, DiRaimondo D, DeSimone R, Raneli G, Avenone G. Non lipid, dose-dependent effects of pravastatin treatment on hemostatic system and inflamma-tory response. Eur J ClM Pharmacol 2000; 56: 277–84.
   Google Scholar
• Miossec P, Zkhiri F, Panes J, David-dufilho M, Devynck MA, Valensi PE. Effect of pravastatin on erythrocyte rheological and biochemical properties in poorly controlled type 2 diabetic patients. Diabet Med 1999; 16: 424–30.
   Google Scholar
• Stenestrand U, Wallentin L, for the Swedish Register for Cardiac Intensive Care (RIKS-HIA). Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 2001; 285: 430–6.
   Google Scholar
• Amtz HR, Wunderlich W, Schnitzer L, Stern R, Fischer F, Agrawal R, Linderer T, Schultheiss HP. Short- and long-term effects of intensified versus conventional antilipidemic therapy in patients with coronary heart disease: results from the Lipid-Coronary Artery Disease (L-CAD) Study. Z Kardiol 1999; 88: 582–90.
   Google Scholar
• Kayircioglu M, Can L, Kultursay H, Payzin S, Turkoglu C. Early use of pravastatin in patients with acute myocardial infarction undergoing coronary angioplasty. Acta Cardiol 2002; 57: 295–302.
   Google Scholar
• Ellis SG, Chew D, Chan A, Whitlow PL, Schneider JP, Topol EJ. Death following creatine kinase-MB elevation after coronary intervention: identification of an early risk period: importance of creatine kinase-MB level, completeness of revascularization, ventricular function, and probable bene-fit of statin therapy. Circulation 2002; 106: 1205–10.
   Google Scholar
• Aronow HD, Topol EJ, Roe MT, Houghtaling PL, Wolski KE, Lincoff AM, Harrington RA, Calif RM, Ohman EM, Kleiman NS, Keltai M, Wilcox RG, Vahan-ian A, Armstrong PW, Lauer MS. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet 2001; 357: 1063–8.
   Google Scholar
• Serruys PW, Foley DP, Jackson G, Bonnier H, Macaya C, Vrolix M, Branzi A, Shephard J, Suryapanta H, de Feyter PJ, Melkert R, van Es GA, Pfister PJ. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; fmal results of the fluvastatin angiographic restenosis (FLARE) trial. Eur Heart J1999; 20: 58–69.
   Google Scholar
• van Boven AJ, Liem A. Fluvastatin on Risk Diminishing After Acute Myocardial Infarction (FLORIDA). Presented at: American Heart Association Scientific Session 2000; November 12–15, 2000; New Orleans, LA. Available at: www.acc.orgieducation/online/trials/aha00/florida.htm. Accessibility verified August 21, 2002.
   Google Scholar
• Heeschen C, Hamm CW, Laufs U, Snapinn S, Bohm M, White HD; Platelet Receptor Inhibition in Ischemic Syn-drome Management (PRISM) Investigators. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 2002; 105: 1446–1452.
   Google Scholar
• Amtz HR. The case for early statin therapy in acute coro-nary syndromes. Cardiol Rev 2002; 10: 91–6.
   Google Scholar
• Blazing MA, De Lemos JA, Dyke CK, Califf RM, Bil-heimer D, Braunwald E. The A-to-Z Trial: methods and rationale for a single trial investigating combined with use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy. Am Heart J 2001; 142: 211–7.
   Google Scholar
• Cannon CP, McCabe CH, Belder R, Breen J, Braunwald E. Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial. Am J Cardiol 2002; 89: 860–861.
   Google Scholar
• Thompson PL. Clinical relevance of statins: instituting treat-ment early in acute coronary syndrome patients. Atheroscler SuppL 2001; 2: 15–9.
   Google Scholar
• Newby LK, Kristinsson A, Bhapkar MV, Aylward PE, Dimas AP, Klein WW, McGuire DK, Molitemo DJ, Verheugt FW, Weaver WD, Califf RM; SYMPHONY and 2nd SYMPHONY Investigators. Sibrafiban vs aspirin to yield maximun protection from ischemic heart events post-acute coronary syndromes. Early statin initiation and outcomes in patients with acute coronary syndromes. JAMA 2002; 287: 3087–95.
   Google Scholar
• Fonarow GC, French WJ, Parsons LS, Sun H, Malmgren JA. Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: data from the National Registry of Myocardial Infarction 3. Circulation 2001; 103: 38–44.
   Google Scholar